We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Guidance to help you plan and prepare for implementing artificial intelligence (AI).
How to apply for a clinical trial including eligibility, phases, model IMPDs, costs and how to make changes to your application.
How to write up and share your findings
How to use a randomised controlled trial to evaluate your digital health product.
A speech by Marcus Bokkerink, Chair of the Competition and Markets Authority (CMA), delivered at the CMA's 10 year anniversary event.
An agreement between DHSC and the ABPI on getting the best value and most effective medicines into use more quickly.
The UK government's design principles and examples of how they've been used.
How to use a quasi-experimental study to evaluate your digital health product.
Emerging techniques on how to prevent or minimise the environmental impacts of post-combustion carbon dioxide capture.
A resource to help local commissioners provide cost-effective interventions for children aged up to 5 and pregnant women.
The independent Inclusion at Work Panel has today published a report on the state of equality, diversity and inclusion (EDI) business practices in the UK.
Why it's important to evaluate digital health products that have been developed rapidly and how to choose evaluation methods in these circumstances.
How to use a cost benefit analysis to evaluate your digital health product.
A speech delivered by Martin Coleman, Non-Executive Director and Panel Chair, Competition and Markets Authority on 'why outcomes matter'. The speech was delivered at the 2024 Informa Competition Law Conference
This is a guide for civil servants to develop better policies by incorporating evaluation into the policymaking process.
We have more than 10 years’ experience of successfully working with our customers to develop solutions across the radioactive waste lifecycle and provide access to the full range of treatment, logistics, and disposal techniques and technology in the UK, Europe,...
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).